Published in J Pharmacol Exp Ther on April 01, 1991
L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Invest (1998) 1.05
L-2-oxothiazolidine-4-carboxylic acid attenuates oxidative stress and inflammation in retinal pigment epithelium. Mol Vis (2014) 0.79
Transport via SLC5A8 (SMCT1) is obligatory for 2-oxothiazolidine-4-carboxylate to enhance glutathione production in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2011) 0.78
L-2-oxothiazolidine-4-carboxylic acid inhibits human immunodeficiency virus type 1 replication in mononuclear phagocytes and lymphocytes. Clin Diagn Lab Immunol (1997) 0.77
Effect of procysteine on aging-associated changes in hepatic GSH and SMase: evidence for transcriptional regulation of smpd3. J Lipid Res (2014) 0.77
Arginine Thiazolidine Carboxylate Stimulates Insulin Secretion through Production of Ca2+-Mobilizing Second Messengers NAADP and cADPR in Pancreatic Islets. PLoS One (2015) 0.75
Localization and thiol dependancy of endogenous nitro compounds-mediating urethral photo-relaxation. Pflugers Arch (2007) 0.75
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol (2000) 2.24
Compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol Appl Pharmacol (1996) 2.00
Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther (1983) 1.79
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol (1989) 1.50
Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat. J Pharmacol Exp Ther (1976) 1.41
Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest (1983) 1.31
The systemic availability of oral glutathione. Eur J Clin Pharmacol (1992) 1.29
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Hepatic glutathione homeostasis in the rat: efflux accounts for glutathione turnover. Hepatology (1984) 1.23
Biliary excretion of glutathione and glutathione disulfide in the rat. Regulation and response to oxidative stress. J Clin Invest (1984) 1.18
Kava hepatotoxicity. Ann Intern Med (2001) 1.13
Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. Hepatology (1995) 1.13
Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS (1992) 1.10
Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett (1997) 1.10
Regulation of hepatic glutathione turnover in rats in vivo and evidence for kinetic homogeneity of the hepatic glutathione pool. J Clin Invest (1981) 1.07
Therapeutic doses of acetaminophen stimulate the turnover of cysteine and glutathione in man. J Hepatol (1987) 1.06
Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). J Biol Chem (1998) 1.03
Altered bile acid metabolism in primary biliary cirrhosis. Dig Dis Sci (1981) 1.03
High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest (1991) 1.01
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer (1998) 1.00
The effects of age and glutathione depletion on hepatic glutathione turnover in vivo determined by acetaminophen probe analysis. J Pharmacol Exp Ther (1980) 1.00
Ethanol suppresses hepatic glutathione synthesis in rats in vivo. J Pharmacol Exp Ther (1984) 0.96
Clinical value of the bile acid breath test. Evaluation of the Mayo Clinic experience. Mayo Clin Proc (1978) 0.96
Stiff-man syndrome with abnormalities in CSF and computerized tomography findings. Report of a case. Arch Neurol (1980) 0.95
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol (2007) 0.94
Success and relapse rate after treatment of cryptorchidism with intranasal LHRH. Acta Paediatr Scand (1985) 0.94
Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer (2001) 0.94
Molecular characteristics of Haemophilus influenzae causing invasive disease during the period of vaccination in Switzerland: analysis of strains isolated between 1986 and 1993. J Clin Microbiol (1996) 0.93
Hepatic functional deterioration after portacaval shunt in the rat. Effects on sulfobromophthalein transport-maximum, indocyanine green clearance and galactose elimination capacity. Gastroenterology (1976) 0.93
Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol (1997) 0.92
Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer (1997) 0.92
Decreased production of glutathione in patients with cirrhosis. Eur J Clin Invest (1987) 0.92
Decreased release of glutathione into the systemic circulation of patients with HIV infection. Eur J Clin Invest (1996) 0.92
A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol (1999) 0.91
Toxic doses of acetaminophen suppress hepatic glutathione synthesis in rats. Hepatology (1982) 0.91
Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br J Cancer (1997) 0.91
Glutathione metabolism in activated human neutrophils: stimulation of glutathione synthesis and consumption of glutathione by reactive oxygen species. Eur J Clin Invest (1991) 0.90
Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter. Genomics (1996) 0.90
Oxidant stress and hepatic necrosis in rats treated with diquat. J Pharmacol Exp Ther (1985) 0.90
Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther (1985) 0.90
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol (2001) 0.89
Divergent effects of intravenous GSH and cysteine on renal and hepatic GSH. Am J Physiol (1992) 0.89
Reperfusion injury of the liver: role of mitochondria and protection by glutathione ester. J Surg Res (1999) 0.89
Oxidation of mitochondrial proteins and DNA following administration of ethanol. Biochem Biophys Res Commun (1995) 0.88
Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. Int J Oncol (1997) 0.87
Effects of hypochlorous acid and chloramines on vascular resistance, cell integrity, and biliary glutathione disulfide in the perfused rat liver: modulation by glutathione. J Hepatol (1991) 0.87
Oxidation of hydrazine metabolites formed from isoniazid. Clin Pharmacol Ther (1985) 0.86
The enigma of young age. Ann Oncol (2006) 0.86
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol (2011) 0.85
Oxidant stress during reperfusion of ischemic liver: no evidence for a role of xanthine oxidase. Hepatology (1988) 0.85
Liver injury due to verapamil. Hepatogastroenterology (1988) 0.85
Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther (1999) 0.85
Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo. J Hepatol (1993) 0.84
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol (2009) 0.84
Breath test with isotopes of carbon: progress and potential. J Lab Clin Med (1977) 0.84
Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos (1998) 0.83
Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol (1986) 0.83
Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. Int J Cancer (2000) 0.83
Fish oil protects mice against acetaminophen hepatotoxicity in vivo. Hepatology (1991) 0.83
Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. J Hepatol (1998) 0.83
Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol (1999) 0.83
Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione. J Pharmacol Exp Ther (1995) 0.82
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer (1999) 0.82
Retinoid receptors in ovarian cancer: expression and prognosis. Ann Oncol (2005) 0.81
Plasmaperfusion for the treatment of intractable pruritus of cholestasis. Mayo Clin Proc (1978) 0.80
Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet (1980) 0.80
Epidermal growth factor enhances cisplatin-induced apoptosis by a caspase 3 independent pathway. Cancer Chemother Pharmacol (2001) 0.80
Chemical nature of reactive intermediates as determinant of toxicologic responses. Drug Metab Rev (1982) 0.80
Decreased glutathione in patients with anorexia nervosa. Risk factor for toxic liver injury? Eur J Clin Nutr (2004) 0.80
PRO_10--a new tissue-based prognostic multigene marker in patients with early estrogen receptor-positive breast cancer. Pathobiology (2011) 0.80
Postischemic ATP levels predict hepatic function 24 hours following ischemia in the rat. Experientia (1988) 0.80
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology (2001) 0.79
Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS. AIDS Res Hum Retroviruses (1995) 0.79
Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid. Eur J Clin Pharmacol (1987) 0.79
Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. Cancer Chemother Pharmacol (2000) 0.79
Assessment of mitochondrial function in vivo with a breath test utilizing alpha-ketoisocaproic acid. Hepatology (1989) 0.79
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol (2006) 0.79
Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid. J Pharmacol Exp Ther (1987) 0.79
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol (2004) 0.79
Effect of allopurinol on oxidant stress and hepatic function following ischemia and reperfusion in the rat. Liver (1988) 0.78
Electrophoretic fractionation of minute protein samples using a micropreparative device. Lab Pract (1976) 0.78
Ovarian cancer. an institutional review of patterns of care, health insurance and prognosis. Eur J Cancer (2000) 0.78
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer (2007) 0.78
Endotoxin causes neutrophil-independent oxidative stress in rats. J Appl Physiol (1985) (1988) 0.78
Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol (1993) 0.78
Cu metabolism in the liver. Adv Exp Med Biol (1999) 0.78
Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. Cancer Chemother Pharmacol (2000) 0.77
Solvent isotope effect on bile formation in the rat. Biochem J (1995) 0.77
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann Oncol (2003) 0.77
Plasma glutathione disulfide as an index of oxidant stress in vivo: effects of carbon tetrachloride, dimethylnitrosamine, nitrofurantoin, metronidazole, doxorubicin and diquat. Res Commun Chem Pathol Pharmacol (1984) 0.77
Ethanol decreases plasma sulphydryls in man: effect of disulfiram. Eur J Clin Invest (1988) 0.77
Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers. Br J Anaesth (2000) 0.77
Mitochondrial function reflected by the decarboxylation of [13C]ketoisocaproate is impaired in alcoholics. Alcohol Clin Exp Res (1994) 0.77
Effect of one month of lactitol treatment on calcium metabolism in man. Eur J Clin Pharmacol (1989) 0.77
Diet and fatty acids: can fish substitute for fish oil? Clin Exp Rheumatol (1991) 0.76